RNXT RenovoRx Forecast, Technical & Fundamental Analysis
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment... Show more
RNXT is expected to report earnings to fall 16.67% to -7 cents per share on August 13
Q2'26
Est.
$-0.08
Q1'26
Missed
by $0.01
Q4'25
Est.
$-0.08
Q3'25
Est.
$-0.08
Q2'25
Beat
by $0.01
The last earnings report on May 14 showed earnings per share of -9 cents, missing the estimate of -7 cents. With 543.48K shares outstanding, the current market capitalization sits at 43.53M.
A.I.dvisor tells us that RNXT and RXRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RNXT and RXRX's prices will move in lockstep.
RNXT sees MACD Histogram crosses below signal line
RNXT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 08, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNXT as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
RNXT moved below its 50-day moving average on July 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RNXT crossed bearishly below the 50-day moving average on July 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNXT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RNXT advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
RNXT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 99 cases where RNXT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.864) is normal, around the industry mean (19.191). P/E Ratio (0.000) is within average values for comparable stocks, (38.162). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (23.981) is also within normal values, averaging (394.782).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RNXT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
